Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $11.0 million.

  • Mimedx's Change in Receivables rose 105571.88% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 37234.98%. This contributed to the annual value of $2.6 million for FY2024, which is 7914.52% down from last year.
  • Per Mimedx's latest filing, its Change in Receivables stood at $11.0 million for Q3 2025, which was up 105571.88% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Change in Receivables peaked at $11.0 million during Q3 2025, and registered a low of -$4.0 million during Q2 2024.
  • Moreover, its 5-year median value for Change in Receivables was $2.4 million (2022), whereas its average is $3.0 million.
  • Per our database at Business Quant, Mimedx's Change in Receivables crashed by 8920000.0% in 2022 and then surged by 105571.88% in 2025.
  • Mimedx's Change in Receivables (Quarter) stood at $9.5 million in 2021, then tumbled by 72.21% to $2.6 million in 2022, then skyrocketed by 111.13% to $5.6 million in 2023, then tumbled by 59.61% to $2.3 million in 2024, then surged by 388.86% to $11.0 million in 2025.
  • Its Change in Receivables stands at $11.0 million for Q3 2025, versus $7.3 million for Q2 2025 and $7.2 million for Q1 2025.